Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

Analyst coverage

Analyst coverage

Firm Analyst
Barclays
 Peter Lawson, D. Phil.
Citi
 David Lebowitz
Cowen and Company
 Marc Frahm, Ph.D.
Goldman, Sachs & Co.
 Salveen Richter
Guggenheim Securities
 Michael Schmidt, Ph.D.
H.C. Wainwright
 Andrew Fein
JMP Securities
 Reni Benjamin, Ph.D.
Leerink
 Andrew Berens, M.D.
Morgan Stanley
 Michael Ulz
Needham & Company
 Ami Fadia
Oppenheimer & Co.
 Matthew Biegler
Piper Sandler
 Chris Raymond
Raymond James
 Laura Prendergast, Ph.D.
Robert W. Baird
 Colleen M. Kusy
Stifel
 Brad Canino
Wedbush PacGrow Life Sciences
 David Nierengarten, Ph.D.
Wells Fargo Securities
 Derek Archila
Blueprint Medicines Corporation is followed by the analysts listed on this page. Please note that any opinions, estimates or forecasts regarding Blueprint Medicines Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Blueprint Medicines Corporation or its management. Blueprint Medicines Corporation does not by its reference here or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.